{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:16:21Z","timestamp":1791504981633,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032297","name":"InfectoPharm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","award":["16GW0249K"],"award-info":[{"award-number":["16GW0249K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cmi.2026.02.024","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:20:57Z","timestamp":1772850057000},"page":"967-974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meropenem and fosfomycin against Klebsiella pneumoniae: Towards a combination breakpoint using a pharmacometric approach"],"prefix":"10.1016","volume":"32","author":[{"given":"Aneeq","family":"Farooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklas","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie L.G.","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.02.024_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-019-0343-8","article-title":"Klebsiella pneumoniae: an increasing threat to public health","volume":"19","author":"Effah","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.cmi.2026.02.024_bib2","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.024_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00634-19","article-title":"The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates","volume":"57","author":"Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.02.024_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: a strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.02.024_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with Gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2026.02.024_bib6","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.024_bib7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/microorganisms13050963","article-title":"Emerging concepts for the treatment of biofilm-associated bone and joint infections with IV fosfomycin: a literature review","volume":"13","author":"Tedeschi","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2026.02.024_bib8","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/jac\/dkae253","article-title":"Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature","volume":"79","author":"Butler","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical Microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.02.024_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","article-title":"Real-world use, effectiveness, and safety of intravenous fosfomycin: the FORTRESS study","volume":"14","author":"Bodmann","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2026.02.024_bib11","series-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 15.0","year":"2025"},{"key":"10.1016\/j.cmi.2026.02.024_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QCO.0000000000000597","article-title":"The role of fosfomycin for multidrug-resistant gram-negative infections","volume":"32","author":"Bassetti","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.024_bib13","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1128\/AAC.03099-15","article-title":"Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae","volume":"60","author":"Albiero","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/antibiotics11020153","article-title":"Assessment of in-vitro synergy of fosfomycin with meropenem, amikacin and tigecycline in whole genome sequenced extended and pan drug resistant Klebsiella pneumoniae: exploring a colistin sparing protocol","volume":"11","author":"Al-Quraini","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2026.02.024_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jac\/dkaf020","article-title":"The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection","volume":"80","author":"MacGowan","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkae459","article-title":"Pharmacokinetic\/pharmacodynamic analysis of meropenem and fosfomycin combinations in in vitro time\u2013kill and hollow-fibre infection models against multidrug-resistant and carbapenemase-producing Klebsiella pneumoniae","volume":"80","author":"Farooq","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.cmi.2026.02.024_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41467-017-01929-y","article-title":"A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions","volume":"8","author":"Wicha","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.02.024_bib19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Autom Control"},{"key":"10.1016\/j.cmi.2026.02.024_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2026.02.024_bib21","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population pharmacokinetics of fosfomycin in critically ill patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cmi.2018.02.005","article-title":"Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli","volume":"24","author":"Merino-Boh\u00f3rquez","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.02.024_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib24","first-page":"264","article-title":"Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains","volume":"46","author":"Della Rocca","year":"2023","journal-title":"New Microbiol"},{"key":"10.1016\/j.cmi.2026.02.024_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/1120009X.2020.1745501","article-title":"In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and\/or NDM-producing Klebsiella pneumoniae","volume":"32","author":"Erturk","year":"2020","journal-title":"J Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-Avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.02.024_bib27","series-title":"Antimicrobial wild type distributions of microorganisms","year":"2025"},{"key":"10.1016\/j.cmi.2026.02.024_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/antibiotics14020139","article-title":"Could a reduced dose of 8 g of continuous infusion fosfomycin be considered as effective as and safer than a standard 16 g dose when combined with high-dose daptomycin in the treatment of Staphylococcal osteoarticular infections?","volume":"14","author":"Cojutti","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2026.02.024_bib29","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/Pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.02.024_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00756-19","article-title":"Quantitative models of phage-antibiotic combination therapy","volume":"5","author":"Rodriguez-Gonzalez","year":"2020","journal-title":"mSystems"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:16:21Z","timestamp":1779999381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1198743X26001023"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meropenem and fosfomycin against Klebsiella pneumoniae: Towards a combination breakpoint using a pharmacometric approach","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}